Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus EGFR-TKIs in EGFR-mutant NSCLC
NCT03720873Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03720873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03720873.